Abstract #1139
Preliminary evidence of a vascular normalization biomarker in trastuzumab-treated HER2+ breast cancer
Anna G. Sorace 1,2 , Jennifer G. Whisenant 1,2 , J. Oliver McIntyre 2,3 , Violeta M. Sanchez 4 , Mary E. Loveless 2 , and Thomas E. Yankeelov 1,2
1
Radiology, Vanderbilt University, Nashville,
Tennessee, United States,
2
Vanderbilt
University Institute of Imaging Science, Vanderbilt
University, Nashville, Tennessee, United States,
3
Cancer
Biology, Vanderbilt University, Nashville, Tennessee,
United States,
4
Hematology
Oncology, Vanderbilt University, Nashville, Tennessee,
United States
We use quantitative DCE-MRI to determine sensitivity to
HER2+ targeted breast cancer treatments early in the
course of therapy. Preclinical studies utilizing mice
with HER2+ (sensitive or resistant) tumors were treated
with trastuzumab or saline. DCE-MRI was longitudinally
tracked from baseline to day 4. DCE-MRI parameter,
K
trans
,
revealed significant increases post treatment in the
HER2+ sensitive, treated tumors compared to their
control counterparts, untreated and HER2+ resistant
treated, therefore suggesting vessel normalization.
Paralleled histological parameter, microvessel density,
also revealed significant increases. Imaging biomarkers
have potential as a noninvasive tool to discriminate
responders from nonresponders early during the course of
therapy.
This abstract and the presentation materials are available to members only;
a login is required.
Join Here
